


Stabilis



Buprenorphine hydrochloride



Tradename

Bunondol	Poland
Buprenex	United States of America
Buprex	Spain
Temgesic	Belgium, Denmark, France, Great Britain, Italy, Netherlands, Norway, Sweden, Tunisia, United Arab Emirates



Stability in solutions

		0,03 mg/ml	1-9°C		180			4314
		0,03 mg/ml	18-24°C		180			4314



Stability of mixtures

PVC		57 mg/ml	21°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30	2113
PVC		57 mg/ml	36°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	9	2113
PVC		57 mg/ml	4°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30	2113
PP		57 mg/ml	21°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30	2113
PP		57 mg/ml	36°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	16	2113

		57 mg/ml	4°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30		2113
--	--	----------	-----	--	---	----	--	------












Factors which affect stability

				4314
--	--	--	--	------



Compatibility

	Buprenorphine hydrochloride : 0.04 mg/ml Allopurinol sodium : 3 mg/ml		307
			921
	Buprenorphine hydrochloride : 0.04 mg/ml Cladribine : 0.5 mg/ml		1496
	Buprenorphine hydrochloride : 0.04 mg/ml Cladribine : 0.015 mg/ml		1496
	Buprenorphine hydrochloride : 0.04 mg/ml		301
	Buprenorphine hydrochloride : 0.04 mg/ml		1415
	Buprenorphine hydrochloride : 0.04 mg/ml Amifostine : 10 mg/ml		3
	Buprenorphine hydrochloride : 0.04 mg/ml Aztreonam : 40 mg/ml		99
	Buprenorphine hydrochloride : 0.04 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Buprenorphine hydrochloride : 0.04 mg/ml Docetaxel : 0.9 mg/ml		1754
			251
	Buprenorphine hydrochloride : 0.04 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Buprenorphine hydrochloride : 0.04 mg/ml Filgrastim : 30 µg/ml		244
			1232
	Buprenorphine hydrochloride : 0.04 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Buprenorphine hydrochloride : 0.04 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
			1625
	Buprenorphine hydrochloride : 0.04 mg/ml Linezolid : 2 mg/ml		1925
	Buprenorphine hydrochloride : 0.04 mg/ml Melphalan : 0.1 mg/ml		169

	Buprenorphine hydrochloride : 0.15 mg/ml Midazolam hydrochloride : 2.5 mg/ml	∅	404
	Buprenorphine hydrochloride : 0,04 mg/ml Oxaliplatin : 0,5 mg/ml	♦	1662
	Buprenorphine hydrochloride : 0.04 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
	Buprenorphine hydrochloride : 0.04 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	♦	81
	Buprenorphine hydrochloride : 0.04 mg/ml Propofol : 10 mg/ml	∅	300
	Buprenorphine hydrochloride : 0.04 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
	Buprenorphine hydrochloride : 0.04 mg/ml Teniposide : 0.1 mg/ml	♦	905
	Buprenorphine hydrochloride : 0.04 mg/ml Thiotepa : 1 mg/ml	♦	249
	Buprenorphine hydrochloride : 0.04 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84



Route of administration



References














































	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
404	Journal	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1232	Journal	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Journal	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.

1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2113	Journal	J?ppinen A, Kokki H, Naaranlahti TJ, Rasi AS. Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 1999 ; 21, 6: 272-274.
4314	Journal	DenHerder J.M, Reed R.L, Sargent J.L, Bobe G, Stevens J.F, Helen E Diggs H.E. Effects of Time and Storage Conditions on the Chemical and Microbiologic Stability of Diluted Buprenorphine for Injection. J Am Pharm Assoc 2017 ; 56, 4: 457-461.



Dictionary

 Analgesic	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Length of time
 Biosimilar	 Conflicting data
 References	 Glass
 NaCl 0,9% + antibacterial	 Protect from light
 Day	 Stability of mixtures
 Solvent	 Compound
 Polyvinyl chloride	 Sodium chloride 0,9%
 Polypropylene	 Factors which affect stability
 Polypropylen Syringe	 Induces
 Reduced stability	 Compatibility
 Compatible	 Immediate precipitation
 Incompatible	 Glucose 5%
 Parenteral nutrition (binary mixture)	 Parenteral nutrition (with lipids)
 Loss of turbidity	 Turbidity in 4 hours
 Water for Injection	 None
 Route of administration	 Intravenous
 Intramuscular	 Sub-cutaneous
 Continuous subcutaneous infusion	 References
 Dictionary	